Key facts

Invented name
  • Mozobil
  • Mozobil
Active Substance
Plerixafor
Therapeutic area
Oncology
Decision number
P/0253/2013
PIP number
EMEA-000174-PIP01-07-M03
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Myelosuppression caused by chemotherapy to treat malignant disorders, which requires an autologous haematopoietic stem cell transplant
Route(s) of administration
  • Subcutaneous use
  • Intravenous use
Contact for public enquiries

Sanofi B.V.

E-mail: eumedinfo.GZ@sanofi.com
Tel. +31 2024 54000
 

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-C-000174-PIP01-07-M03
Compliance opinion date
Compliance outcome
Positive

Decision

P/0253/2013: EMA decision of 29 October 2013 on the acceptance of a modification of an agreed paediatric investigation plan for plerixafor (Mozobil) (EMEA-000174-PIP01-07-M03)

How useful do you find this page?